CSTL (Castle Biosciences) 3-Year RORE % : -39.55% (As of Mar. 2026)


CSTL Castle Biosciences Inc CSTL
73 GF Score
Price $24.11
GF Value $29.18
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences 3-Year RORE %?

Castle Biosciences CSTL -2.47% 73 3-Year RORE % is -39.55 as of Mar. 2026. GuruFocus rates CSTL with a GF Score™ of 73/100 and a GF Value™ of $29.18 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Castle Biosciences ranks worse than 74.13% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Castle Biosciences's 3-Year RORE % for the quarter that ended in Mar. 2026 was -39.55%.

The industry rank for Castle Biosciences's 3-Year RORE % or its related term are showing as below:

CSTL's 3-Year RORE % is ranked worse than
74.13% of 201 companies
in the Medical Diagnostics & Research industry
Industry Median: -7.89 vs CSTL: -39.55

Castle Biosciences  (NAS:CSTL) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Castle Biosciences 3-Year RORE % Related Terms


Castle Biosciences 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Castle Biosciences's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Castle Biosciences 3-Year RORE % Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only 52.78 47.81 15.24 -77.86 -54.62

Castle Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.38 -78.33 -77.60 -54.62 -39.55

CSTL vs FLGT, MYGN, OPK: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, Castle Biosciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Castle Biosciences 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Castle Biosciences's 3-Year RORE % falls into.


CSTL
73GF Score
Castle Biosciences Inc CSTL
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Castle Biosciences 3-Year RORE % Calculation

Castle Biosciences's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.44--1.14 )/( -1.77-0 )
=0.7/-1.77
=-39.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -39.55 mean?
Castle Biosciences (CSTL) has a 3-Year RORE % of -39.55 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Castle Biosciences and its competitors. According to the industry distribution chart, Castle Biosciences ranks #149 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 74.1%.
Is Castle Biosciences' 3-Year RORE % too high?
Castle Biosciences' current 3-Year RORE % is -39.55. Based on the distribution chart, Castle Biosciences ranks #149 out of 201 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Castle Biosciences has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' 3-Year RORE % compare to FLGT and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #149 out of 201 companies for 3-Year RORE %. This places Castle Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current 3-Year RORE % is -39.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.18, compared to a current price of $24.11 — trading 17.4% below its estimated fair value. The current 3-Year RORE % is -39.55. Castle Biosciences' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current 3-Year RORE % is -39.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued. The current stock price of $24.11 is trading 17.4% below its estimated GF Value™ of $29.18. GuruFocus considers Castle Biosciences to be Modestly Undervalued.

Key valuation signals for CSTL:

  • 3-Year RORE %: -39.55
  • GF Value™: $29.18 vs. price of $24.11 (17.4% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
73GF Score

Get the complete analysis for CSTL

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.11
Price
$29.18
GF Value